Solstice Neurosciences Sponsors ‘Universal Pain’ Exhibit at International Museum of Surgical Sciences in Chicago, Illinois

This world-class medical museum is visited by nearly 20,000 visitors annually, 70 percent of whom are professionals, educators, and students involved in the health care industry. In addition to historical artifacts from the museum’s extensive collection, archival manuscripts and artwork highlighting many pioneers and their discoveries in pain management and anesthesia are on display.

“Solstice Neurosciences is delighted that this educational exhibit is opening, and is pleased to help educate the public as to how a toxin might offer pain relief,” said Shawn O’Brien, Chief Executive Officer at Solstice. With October being ‘Movement Disorder Month,’ this timely opening enables Solstice to generate awareness for the condition of Cervical Dystonia (CD) and available treatment options.”

As part of its support to the IMSS to promote awareness and knowledge about CD and the pain associated with it, Solstice’s educational display panel focuses specifically on botulinum toxin, its mechanism of action and its use for treating this painful muscle disorder.

About Solstice Neurosciences, Inc.:

Founded in 2004, Solstice Neurosciences, Inc. is a biopharmaceutical company focused on the development, manufacturing, sales and marketing of specialty products. Solstice’s first product, Myobloc® (Botulinum Toxin Type B) Injectable Solution 5,000U/mL, represents the only botulinum toxin type B currently available to physicians and patients worldwide. MYOBLOC is sold in the United States and approved in Canada. It is also sold and distributed in Europe as NeuroBloc®. MYOBLOC is indicated for the treatment of patients with cervical dystonia (CD) to reduce the severity of abnormal head position and pain associated with CD. For more information about Solstice Neurosciences, Inc., visit www.solsticeneuro.com

About Cervical Dystonia:

Cervical Dystonia (CD), also known as spasmodic torticollis, is a condition that primarily affects the muscles of the head and neck (the cervical area of the spine). Cervical dystonia is the most common dystonia requiring referral to movement disorder clinics. While the exact cause of CD is unknown, scientists believe the problem originates in the basal ganglia area of the brain that is instrumental in movement. Dystonia has an estimated prevalence of over 300,000 cases in North America. In general, there are three main approaches to the treatment of CD: oral medications, surgery, and toxin therapy.

Contact:

Diane Murray
Director of Business Operations & Communications

Phone: Toll Free (866)220-5042, or Direct (267)620-8056